Exchange: NASDAQ·Updated 07:58 PM EDT

DFTX Earnings

Latest Earnings Results: Q2 '26

Reported: Aug 06

Estimated EPS

-$0.54

Reported EPS

-$1.44

Surprise

-166.19%

Estimated Rev

$0M

Reported Rev

---

Surprise

---

Definium Therapeutics reported a net loss of $158.986 million for the three months ended June 30, 2026, with cash, cash equivalents and investments totaling approximately $1.1 billion at period end.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

10-Q

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$0.56
--
--
N/A
Q2 '26
-$0.54
-$1.44
-166.19%
MISSED
Q1 '26
-$0.49
-$0.71
-44.27%
MISSED
Q4 '25
-$0.48
-$0.51
-5.44%
MISSED
Q3 '25
--
-$0.78
--
N/A

Advertisement|Remove ads.